This trial is testing whether adding cabozantinib to avelumab improves treatment of metastatic urothelial cancer.
1 Primary · 3 Secondary · Reporting Duration: Up to 5 years
Active Control
Experimental Treatment
654 Total Participants · 2 Treatment Groups
Primary Treatment: Cabozantinib S-malate · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: